ArticleJAC-antimicrobial resistance2025
Cerebrospinal fluid and plasma pharmacokinetics of ceftazidime/avibactam in a neurocritical patient with CRKP intracranial infection and augmented renal clearance.
Article in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intracranial infections caused by carbapenem-resistant Methods: We utilized validated high-performance liquid chromatography to quantify ceftazidime/avibactam concentrations in paired plasma and CSF samples obtained from a traumatic brain injury patient with CRKP ventriculitis and ARC (CrCl 154.37 mL/min/1.73 m²). The MIC of ceftazidime/avibactam was determined using broth microdilution in accordance with Clinical and Laboratory Standards Institute guidelines. Results: Standard Ceftazidime/avibactam dosing (2.5 g q8h) resulted in subtherapeutic trough concentrations in both plasma (ceftazidime/avibactam: 10.39/0.96 µg/mL) and CSF (ceftazidime/avibactam: 20.4/0.68 µg/mL) against the target pathogen (MIC = 4 mg/L). Dose intensification to 2.5 g q6h administered via 3-h prolonged infusion achieved supra-therapeutic exposures (troughs: plasma 65.60/8.70 µg/mL; CSF 58.90/10.82 µg/mL; CSF/plasma ratio = 0.9 for ceftazidime), which correlated with CSF sterilization and resolution of inflammatory markers. Conclusion: This first-in-human pharmacokinetic evidence in a patient with ARC underscores the inadequacy of conventional ceftazidime/avibactam regimens in this population. Our findings advocate for therapeutic drug monitoring-guided dose optimization incorporating extended infusions to achieve therapeutic targets. These results emphasize the critical need for personalized dosing algorithms in the neurocritical care setting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.